Cellular immunotherapy as a therapeutic approach in multiple myeloma

References

• Myeloma - Cancer Stat Facts [Internet]. [ cited 2018 Jan 4]. Available from: https://seer.cancer.gov/statfacts/html/mulmy.html.
   Google Scholar
• Görgün GT, Whitehill G, Anderson JL, et al. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood. 2013;121:2975–2987.
   PubMed Web of Science ®Google Scholar
• Giannopoulos K, Kaminska W, Hus I, et al. The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma. Br J Cancer. 2012;106:546–552.
   PubMed Web of Science ®Google Scholar
• Muthu Raja KR, Rihova L, Zahradova L, et al. Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma. PloS One. 2012;7:e47077.
   PubMed Web of Science ®Google Scholar
• Brown RD, Pope B, Murray A, et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-β1 and interleukin-10. Blood. 2001;98:2992–2998.
   PubMed Web of Science ®Google Scholar
• Brimnes MK, Svane IM, Johnsen HE. Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma. Clin Exp Immunol. 2006;144:76–84.
   PubMed Web of Science ®Google Scholar
• Ratta M, Fagnoni F, Curti A, et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood. 2002;100:230–237.
   PubMed Web of Science ®Google Scholar
• Brown RD, Pope B, Yuen E, et al. The expression of T cell related costimulatory molecules in multiple myeloma. Leuk Lymphoma. 1998;31:379–384.
   PubMed Web of Science ®Google Scholar
• Chung DJ, Pronschinske KB, Shyer JA, et al. T-cell exhaustion in multiple myeloma relapse after autotransplant: optimal timing of immunotherapy. Cancer Immunol Res. 2016;4:61–71.
   PubMed Web of Science ®Google Scholar
• Zelle-Rieser C, Thangavadivel S, Biedermann R, et al. T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. J Hematol Oncol.J Hematol Oncol. 2016;9:116.
   PubMed Web of Science ®Google Scholar
• Pittari G, Vago L, Festuccia M, et al. Restoring natural killer cell immunity against multiple myeloma in the era of new drugs. Front Immunol. 2017;8:1444.
   PubMed Web of Science ®Google Scholar
• Jinushi M, Vanneman M, Munshi NC, et al. MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci U S A. 2008;105:1285–1290.
   PubMed Web of Science ®Google Scholar
• Carbone E, Neri P, Mesuraca M, et al. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood. 2005;105:251–258.
   PubMed Web of Science ®Google Scholar
• Quach H, Ritchie D, Stewart A, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010;24:22–32.
   PubMed Web of Science ®Google Scholar
• Brown RD, Spencer A, Ho PJ, et al. Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma. Leuk Lymphoma. 2009;50:1860–1864.
   PubMed Web of Science ®Google Scholar
• Hsu AK, Quach H, Tai T, et al. The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood. 2011;117:1605–1613.
   PubMed Web of Science ®Google Scholar
• Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase ib study. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34:2698–2704.
   PubMed Web of Science ®Google Scholar
• Liu J, Hamrouni A, Wolowiec D, et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a myD88-, TRAF6-, and MEK-dependent pathway. Blood. 2007;110:296–304.
   PubMed Web of Science ®Google Scholar
• Wang L, Wang H, Chen H, et al. Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma. Oncotarget. 2015;6:41228–41236.
   PubMedGoogle Scholar
• Ray A, Das DS, Song Y, et al. Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells. Leukemia. 2015;29:1441–1444.
   PubMed Web of Science ®Google Scholar
• Badros A, Hyjek E, Ma N, et al. Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma. Blood. 2017;130:1189–1197.
   PubMed Web of Science ®Google Scholar
• de Weers M, Tai Y-T, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol Baltim Md. 1950;2011(186):1840–1848.
   Google Scholar
• van der Veer MS, de Weers M, van Kessel B, et al. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica. 2011;96:284–290.
   PubMed Web of Science ®Google Scholar
• Hsi ED, Steinle R, Balasa B, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res Off J Am Assoc Cancer Res. 2008;14:2775–2784.
   PubMed Web of Science ®Google Scholar
• Tai Y-T, Dillon M, Song W, et al. Anti-CS1 humanized monoclonal antibody huLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008;112:1329–1337.
   PubMed Web of Science ®Google Scholar
• Collins SM, Bakan CE, Swartzel GD, et al. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunol Immunother CII. 2013;62:1841–1849.
   PubMed Web of Science ®Google Scholar
• Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet Lond Engl. 2016;387:1551–1560.
   PubMed Web of Science ®Google Scholar
• Zonder JA, Mohrbacher AF, Singhal S, et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood. 2012;120:552–559.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:1319–1331.
   PubMed Web of Science ®Google Scholar
• Chari A, Suvannasankha A, Fay JW, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood. 2017;130:974–981.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:754–766.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Lonial S, White D, et al. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. Br J Haematol. 2017;178:896–905.
   PubMed Web of Science ®Google Scholar
• Jakubowiak A, Offidani M, Pégourie B, et al. Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. Blood. 2016;127:2833–2840.
   PubMed Web of Science ®Google Scholar
• van de DNWCJ, Richardson PG, Malavasi F. CD38 antibodies in multiple myeloma: back to the future. Blood. 2018;131:13–29.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Mikhael J, Usmani SZ, et al. Updated results from a phase ib study of isatuximab plus pomalidomide (pom) and dexamethasone (dex) in relapsed/refractory multiple myeloma (RRMM). Blood. 2017;130:1887.
   Web of Science ®Google Scholar
• Martin T, Baz R, Benson DM, et al. A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. Blood. 2017;129:3294–3303.
   PubMed Web of Science ®Google Scholar
• Luetkens T, Yousef S, Shorter C, et al. “In vivo vaccination” effect in clinical responders to anti-myeloma monoclonal antibody isatuximab. Blood. 2017;130:1830.
   Web of Science ®Google Scholar
• Heffner LT, Jagannath S, Zimmerman TM, et al. BT062, an antibody-drug conjugate directed against CD138, given weekly for 3 weeks in each 4 week cycle: safety and further evidence of clinical activity. Blood. 2012;120:4042.
   Web of Science ®Google Scholar
• Kelly KR, Siegel DS, Chanan-Khan AA, et al. Indatuximab ravtansine (BT062) in combination with low-dose dexamethasone and lenalidomide or pomalidomide: clinical activity in patients with relapsed/refractory multiple myeloma. Blood. 2016;128:4486.
   Web of Science ®Google Scholar
• Trudel S, Lendvai N, Popat R, et al. Deep and durable responses in patients (pts) with relapsed/refractory multiple myeloma (MM) treated with monotherapy GSK2857916, an antibody drug conjugate against B-cell maturation antigen (BCMA): preliminary results from part 2 of study BMA117159. Blood. 2017;130:741.
   Web of Science ®Google Scholar
• Baeuerle PA, Bispecific RC. T-cell engaging antibodies for cancer therapy. Cancer Res. 2009;69:4941–4944.
   PubMed Web of Science ®Google Scholar
• Li J, Stagg NJ, Johnston J, et al. Membrane-proximal epitope facilitates efficient T cell synapse formation by anti-FcRH5/CD3 and is a requirement for myeloma cell killing. Cancer Cell. 2017;31:383–395.
   PubMed Web of Science ®Google Scholar
• Seckinger A, Delgado JA, Moser S, et al. Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment. Cancer Cell. 2017;31:396–410.
   PubMed Web of Science ®Google Scholar
• Hipp S, Tai Y-T, Blanset D, et al. A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo. Leukemia. 2017;31:2278.
   PubMed Web of Science ®Google Scholar
• Zafra C de, Balazs M, Fajardo F, et al. Preclinical Characterization of AMG. 424, a novel humanized T cell-recruiting bispecific anti-CD3/CD38 antibody. Blood. 2017;130:500.
   Web of Science ®Google Scholar
• Armeson KE, Hill EG, Costa LJ. Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: meta-analysis of trials with biological assignment. Bone Marrow Transplant. 2013;48:562–567.
   PubMed Web of Science ®Google Scholar
• Bensinger W. Allogeneic stem cell transplantation for multiple myeloma. Hematol Oncol Clin North Am. 2014;28:891–902.
   PubMed Web of Science ®Google Scholar
• Giralt S, Garderet L, Durie B, et al. American society of blood and marrow transplantation, european society of blood and marrow transplantation, blood and marrow transplant clinical trials network, and international myeloma working group consensus conference on salvage hematopoietic cell transplantation in patients with relapsed multiple myeloma. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2015;21:2039–2051.
   PubMed Web of Science ®Google Scholar
• Tricot G, Vesole DH, Jagannath S, et al. Graft-versus-myeloma effect: proof of principle. Blood. 1996;87:1196–1198.
   PubMed Web of Science ®Google Scholar
• Biernacki MA, Tai Y, Zhang GL, et al. Novel myeloma-associated antigens revealed in the context of syngeneic hematopoietic stem cell transplantation. Blood. 2012;119:3142–3150.
   PubMed Web of Science ®Google Scholar
• Tyler EM, Jungbluth AA, O’Reilly RJ, et al. WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions. Blood. 2013;121:308–317.
   PubMed Web of Science ®Google Scholar
• Nwcj VDD, Kröger N, Hegenbart U, et al. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant. 2006;37:1135–1141.
   PubMed Web of Science ®Google Scholar
• Koehne G, Kosuri S, Doubrovina E, et al. Wilms´tumor 1 protein is highly expressed on malignant plasma cells and provides a novel target for immunotherapeutic approaches. Blood. 2015;126:98.
   Web of Science ®Google Scholar
• Szmania S, Gnjatic S, Tricot G, et al. Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma. J Immunother Hagerstown Md. 1997;2007(30):847–854.
   Google Scholar
• Rapoport AP, Aqui NA, Stadtmauer EA, et al. Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. Blood. 2011;117:788–797.
   PubMed Web of Science ®Google Scholar
• Rapoport AP, Aqui NA, Stadtmauer EA, et al. Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells. Clin Cancer Res Off J Am Assoc Cancer Res. 2014;20:1355–1365.
   PubMed Web of Science ®Google Scholar
• Qazilbash MH, Stadtmauer EA, Baladandayuthapani V, et al. Randomized phase II trial of combination idiotype vaccine and anti-CD3/anti-CD28 costimulated autologous T cells in patients with multiple myeloma post-autotransplantation. Blood. 2016;128:4548.
   Web of Science ®Google Scholar
• Noonan KA, Borrello IM. Marrow infiltrating lymphocytes: their role in adoptive immunotherapy. Cancer J. 2015;21:501–505.
   PubMed Web of Science ®Google Scholar
• Noonan K, Matsui W, Serafini P, et al. Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors. Cancer Res. 2005;65:2026–2034.
   PubMed Web of Science ®Google Scholar
• Noonan KA, Huff CA, Davis J, et al. Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma. Sci Transl Med. 2015;7:288ra78.
   PubMed Web of Science ®Google Scholar
• Maiti SN, Huls H, Singh H, et al. Sleeping beauty system to redirect T-cell specificity for human applications. J Immunother Hagerstown Md. 1997;2013(36):112–123.
   Google Scholar
• Beatty GL, Haas AR, Maus MV, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res. 2014;2:112–120.
   PubMed Web of Science ®Google Scholar
• Rapoport AP, Stadtmauer EA, Binder-Scholl GK, et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med. 2015;21:914–921.
   PubMed Web of Science ®Google Scholar
• Linette GP, Stadtmauer EA, Maus MV, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2013;122:863–871.
   PubMed Web of Science ®Google Scholar
• Pentcheva-Hoang T, Torres D, Rodriguez T, et al. Inducible myD88/CD40 (iMC) enhances proliferation and survival of tumor-specific TCR-modified T cells and improves anti-tumor efficacy in myeloma. Blood. 2016;128:4550.
   Web of Science ®Google Scholar
• Vallet S, Pecherstorfer M, Podar K. Adoptive cell therapy in multiple myeloma. Expert Opin Biol Ther. 2017;17:1511–1522.
   PubMed Web of Science ®Google Scholar
• Esensten JH, Bluestone JA, Lim WA. Engineering therapeutic T cells: from synthetic biology to clinical trials. Annu Rev Pathol. 2017;12:305–330.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15:47–62.
   PubMed Web of Science ®Google Scholar
• Garfall AL, Stadtmauer EA, Maus MV, et al. Pilot study of anti-CD19 chimeric antigen receptor T cells (CTL019) in conjunction with salvage autologous stem cell transplantation for advanced multiple myeloma. Blood. 2016;128:974.
   Web of Science ®Google Scholar
• Ali SA, Shi V, Maric I, et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 2016;128:1688–1700.
   PubMed Web of Science ®Google Scholar
• Garfall AL, Lancaster E, Stadtmauer EA, et al. Posterior reversible encephalopathy syndrome (PRES) after infusion of anti-BCMA CAR T cells (CART-BCMA) for multiple myeloma: successful treatment with cyclophosphamide. Blood. 2016;128:5702.
   Web of Science ®Google Scholar
• Cohen AD, Garfall AL, Stadtmauer EA, et al. Safety and efficacy of B-cell maturation antigen (BCMA)-specific chimeric antigen receptor T cells (CART-BCMA) with cyclophosphamide conditioning for refractory multiple myeloma (MM). Blood. 2017;130:505.
   Web of Science ®Google Scholar
• Berdeja JG, Lin Y, Raje N, et al. Durable clinical responses in heavily pretreated patients with relapsed/refractory multiple myeloma: updated results from a multicenter study of bb2121 anti-BCMA CAR T cell therapy. Blood. 2017;130:740.
   Web of Science ®Google Scholar
• Xiaohu FF, Zhao W, Liu J, et al. Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma. J Clin Oncol. 2017;35:LBA3001–LBA3001.
   Web of Science ®Google Scholar
• Ramos CA, Savoldo B, Torrano V, et al. Clinical responses with T lymphocytes targeting malignancy-associated κ light chains. J Clin Investig. 2016;126:2588–2596.
   PubMed Web of Science ®Google Scholar
• Guo B, Chen M, Han Q, et al. CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma. J Cell Immunother. 2016;2:28–35.
   Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al. Long-term follow-up ZUMA-1: A pivotal trial of axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-hodgkin lymphoma (NHL). Blood. 2017;130:578.
   Web of Science ®Google Scholar
• Qin H, Nguyen SM, Ramakrishna S, et al. Novel CD19/CD22 bicistronic chimeric antigen receptors outperform single or bivalent cars in eradicating CD19+CD22+, CD19-, and CD22- pre-b leukemia. Blood. 2017;130:810.
   Web of Science ®Google Scholar
• Locke FL, Westin JR, Miklos DB, et al. Phase 1 results from ZUMA-6: axicabtagene ciloleucel (axi-cel; KTE-C19) in combination with atezolizumab for the treatment of patients with refractory diffuse large b cell lymphoma (DLBCL). Blood. 2017;130:2826.
   Web of Science ®Google Scholar
• Szmania S, Lapteva N, Garg T, et al. Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients. J Immunother Hagerstown Md. 1997;2015(38):24–36.
   Google Scholar
• Chu J, Deng Y, Benson DM, et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia. 2014;28:917–927.
   PubMed Web of Science ®Google Scholar
• Schmitt M, Schmitt A, Rojewski MT, et al. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood. 2008;111:1357–1365.
   PubMed Web of Science ®Google Scholar
• Greiner J, Schmitt A, Giannopoulos K, et al. High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Haematologica. 2010;95:1191–1197.
   PubMed Web of Science ®Google Scholar
• Tsuboi A, Oka Y, Nakajima H, et al. Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma. Int J Hematol. 2007;86:414–417.
   PubMed Web of Science ®Google Scholar
• Goodyear OC, Pratt G, McLarnon A, et al. Differential pattern of CD4+ and CD8+ T-cell immunity to MAGE-A1/A2/A3 in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma. Blood. 2008;112:3362–3372.
   PubMed Web of Science ®Google Scholar
• van Rhee F, Szmania SM, Zhan F, et al. NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood. 2005;105:3939–3944.
   PubMed Web of Science ®Google Scholar
• Jungbluth AA, Ely S, DiLiberto M, et al. The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood. 2005;106:167–174.
   PubMed Web of Science ®Google Scholar
• Avigan D, Rosenblatt J, Kufe D. Dendritic/tumor fusion cells as cancer vaccines. Semin Oncol. 2012;39:287–295.
   PubMed Web of Science ®Google Scholar
• Nooka AK, Wang M, Yee AJ, et al. Final results of a phase 1/2a, dose escalation study of pvx-410 multi-peptide cancer vaccine in patients with smoldering multiple myeloma (SMM). Blood. 2016;128:2124.
   Google Scholar
• Lu C, Meng S, Jin Y, et al. A novel multi-epitope vaccine from MMSA-1 and DKK1 for multiple myeloma immunotherapy. Br J Haematol. 2017;178:413–426.
   PubMed Web of Science ®Google Scholar
• Hayashi T, Hideshima T, Akiyama M, et al. Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes. Blood. 2003;102:1435–1442.
   PubMed Web of Science ®Google Scholar
• Borrello IM, Noonan K, Huff CA, et al. Allogeneic myeloma GVAX with lenalidomide enhances progression free survival through the generation of tumor specific immunity in patients in near complete remission. Blood. 2015;126:4238.
   Web of Science ®Google Scholar
• Tacken PJ, Ijm DV, Torensma R, et al. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol. 2007;7:790–802.
   PubMed Web of Science ®Google Scholar
• Lacy MQ, Mandrekar S, Dispenzieri A, et al. Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival. Am J Hematol. 2009;84:799–802.
   PubMed Web of Science ®Google Scholar
• Gong J, Chen D, Kashiwaba M, et al. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med. 1997;3:558–561.
   PubMed Web of Science ®Google Scholar
• Rosenblatt J, Vasir B, Uhl L, et al. Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood. 2011;117:393–402.
   PubMed Web of Science ®Google Scholar
• Rosenblatt J, Avivi I, Vasir B, et al. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res Off J Am Assoc Cancer Res. 2013;19:3640–3648.
   PubMed Web of Science ®Google Scholar
• Luptakova K, Rosenblatt J, Glotzbecker B, et al. Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol Immunother CII. 2013;62:39–49.
   PubMed Web of Science ®Google Scholar
• Leone P, Berardi S, Frassanito MA, et al. Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8+ T-cell killing. Blood. 2015;126:1443–1451.
   PubMed Web of Science ®Google Scholar
• Radhakrishnan SV, Luetkens T, Yousef S, et al. Chimeric antigen receptor (CAR) T cells specific for CD229: a potentially curative approach for multiple myeloma. Blood. 2017;130:3142.
   Web of Science ®Google Scholar
• Smith EL, Mailankody S, Ghosh A, et al. Development and evaluation of a human single chain variable fragment (scFv) derived BCMA targeted CAR T cell vector leads to a high objective response rate in patients with advanced MM. Blood. 2017;130:742.
   PubMed Web of Science ®Google Scholar
• Wang X, Barnett BE, Martin C, et al. Production of universal anti-BCMA CAR-T cells with reduced alloreactivity, but potent effector function for the treatment of multiple myeloma. Blood. 2017;130:503.
   Web of Science ®Google Scholar
• Mathur R, Zhang Z, He J, et al. Universal SLAMF7-specific CAR T-cells as treatment for multiple myeloma. Blood. 2017;130:502.
   Web of Science ®Google Scholar
• Paulis LE, Mandal S, Kreutz M, et al. Dendritic cell-based nanovaccines for cancer immunotherapy. Curr Opin Immunol. 2013;25:389–395.
   PubMed Web of Science ®Google Scholar